[ad_1]

  • HC Wainwright has initiated coverage on Genenta Science SpA GNTA with a Buy rating and a price target of $25.
  • “We like Genenta’s approach as we believe it presents key advantages and differentiating elements when compared to other cellular therapies in the oncology space: 

    • It leverages a subpopulation of tumor-associated myeloid cells (TEMs), which promote angiogenesis, tumor growth and inhibit anti-tumor immune responses.
    • It is built using an embedded regulatory mechanism to control transgene expression and avoid off-target and systemic toxicity.
    • It has the potential for long-term durability.
    • It is agnostic as it is not restricted to a preselected tumor antigen or a specific tumor type; therefore, it may find broad application for various malignancies.

  • In May, Genenta Science’s ongoing trial of Temferon in glioblastoma multiforme patients with an unmethylated MGMT gene promoter has escalated to the next planned dose
  • With no drug-limiting toxicities observed at lower doses, Genenta has now dosed the first patient in a new cohort (cohort 6) with 3.0 x 106 Temferon cells per kilogram, 50% higher than the highest prior level. 
  • Genenta expects to complete enrollment and dosing in cohorts 6 and 7 by the end of the first half of 2023.
  • Price Action: GNTA shares are down 9.35% at $6.11 during the market session on the last check Monday.

[ad_2]

Source link